Showing 4161-4170 of 5092 results for "".
- Report: AI Skin Technology on The Risehttps://practicaldermatology.com/news/report-ai-skin-technology-on-the-rise/2461428/Perfect Corp.’s latest Global Beauty Trend Report, “The Rise of AI Skin Technology” documents the rise in consumer interest in skin car
- IFPA Launches All the Colors We Are to Call Attention to Diversity in Psoriatic Diseaseshttps://practicaldermatology.com/news/ifpa-launches-all-the-colors-we-are-to-call-attention-to-diversity-in-psoriatic-diseases/2461419/IFPA is launching a new image library that raises awareness of diversity in psoriatic disease. IFPA is the global organization representing all people with psoriatic disease,. Go to any image database, and type “psoriasis” in the search bar. The results? Invariably
- Monkeypox Update: Kids Aged 8 or Younger at High Risk for More Severe Monkeypoxhttps://practicaldermatology.com/news/monkey-pox-update-kids-aged-8-or-younger-at-high-risk-for-more-severe-monkeypox/2461409/Children aged 8 years or younger are at high risk for more severe monkeypox disease, reports The Pediatric Infectious Disease Journal. Young children would be a key target group for smallpox vaccination and other urgent measures if the outbreak widens, according to the review b
- EWG: FDA Must Ban Oxybenzone in Sunscreen Now!https://practicaldermatology.com/news/ewg-fda-must-ban-oxybenzone-in-sunscreen-now/2461405/The U.S. Food and Drug Administration (FDA) should ban oxybenzone in sunscreens, according to researchers at the Environmental Working Group (EWG). For decades, sunscreen makers have used oxybenzone in their products, despite concerns about its health harms. In 2021, the FDA t
- Kintor Pharma Completes Enrollment and Dosing in Phase I Clinical Trial of AGA, Acne Drughttps://practicaldermatology.com/news/kintor-pharma-completes-enrollment-and-dosing-in-phase-i-clinical-trial-of-aga-acne-drug/2461404/Kintor Pharmaceutical Limited has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne. Developed through Kintor Pharma's proprietary Proteolysis Targeting Chimera (PROTAC) platfo
- Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosishttps://practicaldermatology.com/news/seborrheic-dermatitis-survey-shows-burdensome-and-lengthy-path-to-diagnosis/2461396/Arcutis Biotherapeutics, Inc., shared results of a nationwide survey of adults with seborrheic dermatitis and the health care providers who treat them that highlights the long path to diagnosis and the general lack of awareness and education about the disease. The online survey was conducted by T
- Extreme Weather and Skin Disease: What’s the Connection?https://practicaldermatology.com/news/extreme-weather-and-skin-disease-whats-the-connection/2461395/As floods, wildfires, and extreme heat events increase in frequency and severity, they pose a significant threat to global dermatological health, as many skin diseases are climate sensitive, according to The Journal of Climate Change and Health. “We wanted to provide dermatol
- Aesthetics Biomedical's Vivace Ultra Wins FDA Clearancehttps://practicaldermatology.com/news/aesthetics-biomedicals-vivace-ultra/2461390/The FDA has given the nod to Aesthetics Biomedical Inc.’s Vivace Ultra for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. An innovative reimagination and technical upgrade of the legacy Vivace Microneedle RF device, the Vivace Ultra comb
- Study: Psoriasis Does Not Appear to Increase Heart Attack Risk in People with Significant Kidney Diseasehttps://practicaldermatology.com/news/study-psoriasis-does-not-appear-to-increase-heart-attack-risk-in-people-with-significant-kidney-disease/2461387/Studies have suggested that psoriasis is an independent risk factor for heart attack in the general population, but investigators recently found that in people who also have end-stage renal disease, which shares many risk factors with heart disease, it is not. “There are a lot of
- Hugel Resubmits Botulax BLA to FDAhttps://practicaldermatology.com/news/hugel-resubmits-botulax-bla-to-fda-1/2461380/Hugel resubmitted the BLA for its botulinum toxin called Botulax for smoothing glabellar lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) to advance into the U.S. market i